Outlook Therapeutics, Inc. (OTLK) 2019年年度报告「NASDAQ」.pdf

1、 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30,2019 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934

2、For the transition period from to Commission File Number:001-37759 OUTLOOK THERAPEUTICS,INC.(Exact name of registrant as specified in its charter)Delaware 38-3982704(State or other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)7 Clarke DriveCranbury,New Jersey 08512(

3、Address of principal executive offices)(Zip Code)(609)619-3990(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon StockOTLKThe Nasdaq Stock Market LLCSeries A W

4、arrantsOTLKWThe Nasdaq Stock Market LLC Securities Registered Pursuant to Section 12(g)of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No x Indicate by check mark if the registrant is not required to file repor

5、ts pursuant to Section 13 or Section 15(d)of the Act.Yes No x Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during thepreceding 12 months(or for such shorter period than the registrant was requi

6、red to file such reports),and(2)has been subject to such filing requirements for thepast 90 days.Yes x No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of RegulationS-T(232.405 of this chapter)duri